Patrice Penfornis
Overview
Explore the profile of Patrice Penfornis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
884
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sitta J, De Carlo F, Kirven I, Tackett J, Penfornis P, Dobbins G, et al.
Int J Mol Sci
. 2025 Jan;
25(24.
PMID: 39769460
Oncolytic virotherapy has shown great promise in mediating targeted tumor destruction through tumor-selective replication and induction of anti-tumor immunity; however, obstacles remain for virus candidates to reach the clinic. These...
2.
Singh S, De Carlo F, Ibrahim M, Penfornis P, Mouton A, Tripathi S, et al.
Int J Mol Sci
. 2023 May;
24(9).
PMID: 37175448
Since aerobic glycolysis was first observed in tumors almost a century ago by Otto Warburg, the field of cancer cell metabolism has sparked the interest of scientists around the world...
3.
Khan M, Mahdi F, Penfornis P, Akins N, Hossain M, Kim S, et al.
Bioorg Med Chem
. 2023 Jan;
78:117137.
PMID: 36603398
In cancer cells, glutaminolysis is the primary source of biosynthetic precursors. Recent efforts to develop amino acid analogues to inhibit glutamine metabolism in cancer have been extensive. Our lab recently...
4.
Haider S, Penfornis P, Claudio P, McChesney J, Chittiboyina A
Eur J Med Chem
. 2021 Oct;
227:113891.
PMID: 34656042
TumorSelect® is an anticancer technology that combines cytotoxics, nanotechnology, and knowledge of human physiology to develop innovative therapeutic interventions with minimal undesirable side effects commonly observed in conventional chemotherapy. Tumors...
5.
Penfornis P, Fernandes J, Pochampally R
Sci Rep
. 2018 Jan;
8(1):1720.
PMID: 29379063
Human mesenchymal stem/stromal cells (hMSCs) provide support for cancer progression, partly through their secretome that includes extracellular vesicles (EVs). Based on deep-sequencing of small RNA from EVs of MSCs, we...
6.
Vallabhaneni K, Penfornis P, Xing F, Hassler Y, Adams K, Mo Y, et al.
Oncotarget
. 2018 Jan;
8(66):109861-109876.
PMID: 29299114
Mesenchymal stromal cells (hMSCs) have been used to understand the stromal cell properties in solid tumors because of their ablity to differentiate into most cell types. We investigated the role...
7.
Penfornis P, Vallabhaneni K, Janorkar A, Pochampally R
Front Biosci (Elite Ed)
. 2016 Nov;
9(1):162-173.
PMID: 27814597
It is well recognized that one of the major drawbacks of using traditional two dimensional cultures to model the living systems is inaccurately reflecting the physiological manner in which modulators,...
8.
Penfornis P, Pochampally R
Methods Mol Biol
. 2016 May;
1416:159-69.
PMID: 27236671
Mesenchymal stem/stromal cells (MSCs) have been extensively investigated for their potential to regenerate tissue, to modulate the immune system, and their wound healing properties in over 350 clinical trials worldwide....
9.
Nawaz M, Fatima F, Vallabhaneni K, Penfornis P, Valadi H, Ekstrom K, et al.
Stem Cells Int
. 2015 Dec;
2016:1073140.
PMID: 26649044
Stem cells are proposed to continuously secrete trophic factors that potentially serve as mediators of autocrine and paracrine activities, associated with reprogramming of the tumor microenvironment, tissue regeneration, and repair....
10.
Whitt J, Vallabhaneni K, Penfornis P, Pochampally R
Curr Stem Cell Res Ther
. 2015 Oct;
11(2):141-8.
PMID: 26423301
Mesenchymal Stem/stromal cell (MSCs) transplantation procedures have been used since the 1960's to treat leukemia and other diseases, but due to the risks involved only patients with life threatening illnesses...